VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2021 | Venetoclax plus azacitidine in treatment-naïve HR-MDS

Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, gives an overview of the findings of an ongoing Phase Ib study (NCT02942290) of venetoclax plus azacitidine for patients with treatment-naïve high-risk myelodysplastic syndromes (HR-MDS). Prof. Wei reports that 78 patients with HR-MDS have been treated on the trial thus far and comments on the safety findings. The majority of patients had venetoclax dose interruptions due to adverse events. The intention-to-treat overall response rate was 80%, with 40% of patients achieving a complete response (CR) and a median time to CR of 2.6 months. 23% of patients went on to receive allogeneic transplantation. Prof. Wei also discusses the impact of biomarkers on outcomes with this treatment regimen. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Andrew Wei, MBBS, PhD, has received research grants from Abbvie, Amgen, AstraZeneca, Celgene/BMS, Novartis, Servier and F. Hoffmann-La Roche; has received honoraria from Abbvie, Amgen, Astellas, AstraZeneca, Celgene/BMS, Genentech, Janssen, MacroGenics, Novartis, Pfizer, and Servier; has participated in advisory boards for Abbvie, Amgen, Astellas, AstraZeneca, Celgene/BMS, Genentech, Janssen, MacroGenics, Novartis, Pfizer, and Servier; has participated in speakers bureau for Novartis, Abbvie and Celgene/BMS, has participated in consultancy work for Servier; is a former employee of the Walter and Eliza Hall Institute, and is eligible for a fraction of the royalty stream related to Venetoclax.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter